"\"{'index': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152], 'columns': ['seq_num', 'section', 'diff_type', 'base_text', 'compare_text', 'confidence_score'], 'data': [[1, 'Table of Contents', 0, 'SIGNATURE PAGES', '1 SIGNATURE PAGES', 1.0], [2, 'Table of Contents', 0, 'Protocol Approval', 'Protocol Approval', 1.0], [3, 'Table of Contents', 0, 'Investigator Agreement', 'Investigator Agreement', 1.0], [4, 'Table of Contents', 0, 'TABLE OF CONTENTS', 'TABLE OF CONTENTS', 1.0], [5, 'Table of Contents', 0, 'PROTOCOL SYNOPSIS', '2 PROTOCOL SYNOPSIS', 1.0], [6, 'Table of Contents', 0, 'LIST OF ABBREVIATIONS', '3 LIST OF ABBREVIATIONS', 1.0], [7, 'Table of Contents', 0, 'BACKGROUND INFORMATION', '4 BACKGROUND INFORMATION', 1.0], [8, 'Table of Contents', 2, '', 'Table 1 Treatment Guidelines and Prescribing Information for Renal Anemia in NDD-CKD', 0.06896551724137931], [9, 'Table of Contents', 0, 'Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors', 'Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors', 1.0], [10, 'Table of Contents', 0, 'Summary of Clinical Experience', 'Summary of Clinical Experience', 1.0], [11, 'Table of Contents', 0, 'Potential Benefits and Risks', 'Potential Benefits and Risks', 1.0], [12, 'Table of Contents', 0, 'STUDY OBJECTIVES AND ENDPOINTS', '5 STUDY OBJECTIVES AND ENDPOINTS', 1.0], [13, 'Table of Contents', 0, 'Primary Objective', 'Primary Objective', 1.0], [14, 'Table of Contents', 0, 'Primary Efficacy Endpoint', 'Primary Efficacy Endpoint', 1.0], [15, 'Table of Contents', 0, 'Secondary Efficacy Endpoints', 'Secondary Efficacy Endpoints', 1.0], [16, 'Table of Contents', 0, 'Safety Endpoints', 'Safety Endpoints', 1.0], [17, 'Table of Contents', 0, 'STUDY DESIGN', '6 STUDY DESIGN', 1.0], [18, 'Table of Contents', 0, 'Study Design', 'Study Design', 1.0], [19, 'Table of Contents', 0, 'Rationale for Study Design', 'Rationale for Study Design', 1.0], [20, 'Table of Contents', 0, 'Dose Justification', 'Dose Justification', 1.0], [21, 'Table of Contents', 0, 'Independent Data Monitoring Committee', 'Independent Data Monitoring Committee', 1.0], [22, 'Table of Contents', 0, 'Endpoint Adjudication Committee', 'Endpoint Adjudication Committee', 1.0], [23, 'Table of Contents', 0, 'SELECTION AND WITHDRAWAL OF SUBJECTS', '7 SELECTION AND WITHDRAWAL OF SUBJECTS', 1.0], [24, 'Table of Contents', 0, 'General Criteria', 'General Criteria', 1.0], [25, 'Table of Contents', 0, 'Inclusion Criteria', 'Inclusion Criteria', 1.0], [26, 'Table of Contents', 0, 'Exclusion Criteria', 'Exclusion Criteria', 1.0], [27, 'Table of Contents', 0, 'Retesting and Rescreening', 'Retesting and Rescreening', 1.0], [28, 'Table of Contents', 0, 'Retesting', '7.4.1 Retesting', 1.0], [29, 'Table of Contents', 0, 'Rescreening', '7.4.2 Rescreening', 1.0], [30, 'Table of Contents', 3, 'Subject Completion, Study Discontinuation, and Withdrawal of Subjects', 'Study Completion, Subject Completion, Study Discontinuation, and Withdrawal of Subjects', 0.8846153846153846], [31, 'Table of Contents', 2, '', '7.5.1 Study Completion', 0.10526315789473684], [32, 'Table of Contents', 0, 'Subject Completion', '7.5.2 Subject Completion', 1.0], [33, 'Table of Contents', 0, 'Entire Study Termination', '7.5.3 Entire Study Termination', 1.0], [34, 'Table of Contents', 0, 'Individual Study Site Termination', '7.5.4 Individual Study Site Termination', 1.0], [35, 'Table of Contents', 0, 'Individual Subject Discontinuation', '7.5.5 Individual Subject Discontinuation', 1.0], [36, 'Table of Contents', 0, 'Temporary Interruption of Study Medication', 'Temporary Interruption of Study Medication', 1.0], [37, 'Table of Contents', 0, 'Permanent Discontinuation of Study Medication', 'Permanent Discontinuation of Study Medication', 1.0], [38, 'Table of Contents', 0, 'Complete Withdrawal from Further Study Visits/Assessments', 'Complete Withdrawal from Further Study Visits/Assessments', 1.0], [39, 'Table of Contents', 0, 'Procedures to Encourage Continued Study Participation', 'Procedures to Encourage Continued Study Participation', 1.0], [40, 'Table of Contents', 0, 'Procedures to Prevent \\u201cLost to Follow-up\\u201d', 'Procedures to Prevent \\u201cLost to Follow-up\\u201d', 1.0], [41, 'Table of Contents', 0, 'STUDY PRODUCT AND TREATMENT OF SUBJECTS', '8 STUDY PRODUCT AND TREATMENT OF SUBJECTS', 1.0], [42, 'Table of Contents', 0, 'Study Product, Supplies, and Storage', 'Study Product, Supplies, and Storage', 1.0], [43, 'Table of Contents', 0, 'Vadadustat', '8.1.1 Vadadustat', 1.0], [44, 'Table of Contents', 0, 'Darbepoetin Alfa', '8.1.2 Darbepoetin Alfa', 1.0], [45, 'Table of Contents', 0, 'Dispensing Procedures', 'Dispensing Procedures', 1.0], [46, 'Table of Contents', 0, 'Dispensing of Vadadustat', '8.2.1 Dispensing of Vadadustat', 1.0], [47, 'Table of Contents', 0, 'Dispensing of Darbepoetin Alfa', '8.2.2 Dispensing of Darbepoetin Alfa', 1.0], [48, 'Table of Contents', 0, 'Product Accountability and Destruction', 'Product Accountability and Destruction', 1.0], [49, 'Table of Contents', 0, 'Treatment of Subjects', 'Treatment of Subjects', 1.0], [50, 'Table of Contents', 0, 'Treatment Group Assignments', '8.4.1 Treatment Group Assignments', 1.0], [51, 'Table of Contents', 0, 'Randomization', '8.4.2 Randomization', 1.0], [52, 'Table of Contents', 0, 'Blinding', '8.4.3 Blinding', 1.0], [53, 'Table of Contents', 0, 'Dosing and Dose Adjustment Guidelines', '8.4.4 Dosing and Dose Adjustment Guidelines', 1.0], [54, 'Table of Contents', 0, 'Vadadustat Dosing and Dose Adjustment Guidelines', 'Vadadustat Dosing and Dose Adjustment Guidelines', 1.0], [55, 'Table of Contents', 0, 'Darbepoetin Alfa Dosing and Dose Adjustment Guidelines', 'Darbepoetin Alfa Dosing and Dose Adjustment Guidelines', 1.0], [56, 'Table of Contents', 0, 'Late or Missed Doses', '8.4.5 Late or Missed Doses', 1.0], [57, 'Table of Contents', 0, 'Iron Supplementation', '8.4.6 Iron Supplementation', 1.0], [58, 'Table of Contents', 0, 'Rescue Therapy', '8.4.7 Rescue Therapy', 1.0], [59, 'Table of Contents', 0, 'ESA Rescue (Optional)', 'ESA Rescue (Optional)', 1.0], [60, 'Table of Contents', 0, 'Red Blood Cell Transfusion', 'Red Blood Cell Transfusion', 1.0], [61, 'Table of Contents', 0, 'Phlebotomy', '8.4.8 Phlebotomy', 1.0], [62, 'Table of Contents', 0, 'Treatment Compliance', '8.4.9 Treatment Compliance', 1.0], [63, 'Table of Contents', 0, 'Continuation of Treatment', '8.4.10 Continuation of Treatment', 1.0], [64, 'Table of Contents', 0, 'Prior and Concomitant Therapy', 'Prior and Concomitant Therapy', 1.0], [65, 'Table of Contents', 0, 'General', '8.5.1 General', 1.0], [66, 'Table of Contents', 0, 'Investigational Medications', '8.5.2 Investigational Medications', 1.0], [67, 'Table of Contents', 0, 'STUDY PROCEDURES AND SCHEDULE OF ACTIVITIES', '9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITIES', 1.0], [68, 'Table of Contents', 0, 'Administrative Procedures', 'Administrative Procedures', 1.0], [69, 'Table of Contents', 0, 'Informed Consent', '9.1.1 Informed Consent', 1.0], [70, 'Table of Contents', 0, 'Documentation of Screen Failures', '9.1.2 Documentation of Screen Failures', 1.0], [71, 'Table of Contents', 0, 'Contraception and Pregnancy Avoidance Measures', '9.1.3 Contraception and Pregnancy Avoidance Measures', 1.0], [72, 'Table of Contents', 0, 'Laboratory Accreditation and Reference Ranges', '9.1.4 Laboratory Accreditation and Reference Ranges', 1.0], [73, 'Table of Contents', 0, 'Study Procedures and Evaluations', 'Study Procedures and Evaluations', 1.0], [74, 'Table of Contents', 0, 'Clinical Evaluations', '9.2.1 Clinical Evaluations', 1.0], [75, 'Table of Contents', 0, 'Laboratory Evaluations', '9.2.2 Laboratory Evaluations', 1.0], [76, 'Table of Contents', 0, 'Schedule of Activities', 'Schedule of Activities', 1.0], [77, 'Table of Contents', 0, 'Pre-Screening Visit', '9.3.1 Pre-Screening Visit', 1.0], [78, 'Table of Contents', 0, 'Screening Visits', '9.3.2 Screening Visits', 1.0], [79, 'Table of Contents', 0, 'Screening Visit 1 (SV1)', 'Screening Visit 1 (SV1)', 1.0], [80, 'Table of Contents', 0, 'Screening Visit 2 (SV2)', 'Screening Visit 2 (SV2)', 1.0], [81, 'Table of Contents', 0, 'Subject Retesting', 'Subject Retesting', 1.0], [82, 'Table of Contents', 0, 'Subject Rescreening', '9.3.3 Subject Rescreening', 1.0], [83, 'Table of Contents', 0, 'Baseline Visit (Day 1)', '9.3.4 Baseline Visit (Day 1)', 1.0], [84, 'Table of Contents', 0, 'Year 1 Treatment Period Visits (Day 2 through Week 52)', '9.3.5 Year 1 Treatment Period Visits (Day 2 through Week 52)', 1.0], [85, 'Table of Contents', 0, 'Year 2 Treatment Period Visits (Weeks 53 through 104)', '9.3.6 Year 2 Treatment Period Visits (Weeks 53 through 104)', 1.0], [86, 'Table of Contents', 0, 'Year 3/4 Treatment Period Visits (Weeks 116 through 208)', '9.3.7 Year 3/4 Treatment Period Visits (Weeks 116 through 208)', 1.0], [87, 'Table of Contents', 0, 'End-of-Treatment Visit', '9.3.8 End-of-Treatment Visit', 1.0], [88, 'Table of Contents', 0, 'Follow-Up Visit', '9.3.9 Follow-Up Visit', 1.0], [89, 'Table of Contents', 0, 'ADVERSE EVENTS', '10 ADVERSE EVENTS', 1.0], [90, 'Table of Contents', 0, 'Definitions', 'Definitions', 1.0], [91, 'Table of Contents', 0, 'Adverse Events', '10.1.1 Adverse Events', 1.0], [92, 'Table of Contents', 0, 'Serious Adverse Events', '10.1.2 Serious Adverse Events', 1.0], [93, 'Table of Contents', 0, 'Eliciting Adverse Event Information', 'Eliciting Adverse Event Information', 1.0], [94, 'Table of Contents', 0, 'Reporting', 'Reporting', 1.0], [95, 'Table of Contents', 0, 'Reporting Period', '10.3.1 Reporting Period', 1.0], [96, 'Table of Contents', 0, 'Reporting AEs', '10.3.2 Reporting AEs', 1.0], [97, 'Table of Contents', 0, 'Reporting SAEs', '10.3.3 Reporting SAEs', 1.0], [98, 'Table of Contents', 0, 'Reporting Study Endpoints', '10.3.4 Reporting Study Endpoints', 1.0], [99, 'Table of Contents', 0, 'Relationship to Study Medication', '10.3.5 Relationship to Study Medication', 1.0], [100, 'Table of Contents', 0, 'Severity', '10.3.6 Severity', 1.0], [101, 'Table of Contents', 0, 'Follow-Up of Unresolved Events', '10.3.7 Follow-Up of Unresolved Events', 1.0], [102, 'Table of Contents', 0, 'Exposure In Utero', 'Exposure In Utero', 1.0], [103, 'Table of Contents', 0, 'Special Situations', 'Special Situations', 1.0], [104, 'Table of Contents', 0, 'DATA ANALYSIS', '11 DATA ANALYSIS', 1.0], [105, 'Table of Contents', 0, 'Sample Size Determination', 'Sample Size Determination', 1.0], [106, 'Table of Contents', 0, 'Sample Size for the Primary Efficacy Endpoint', '11.1.1 Sample Size for the Primary Efficacy Endpoint', 1.0], [107, 'Table of Contents', 0, 'Sample Size for the Primary Safety Endpoint', '11.1.2 Sample Size for the Primary Safety Endpoint', 1.0], [108, 'Table of Contents', 0, 'Study Analysis Populations', 'Study Analysis Populations', 1.0], [109, 'Table of Contents', 0, 'Analysis of Demographic and Pretreatment Variables', 'Analysis of Demographic and Pretreatment Variables', 1.0], [110, 'Table of Contents', 0, 'Disposition of Subjects', 'Disposition of Subjects', 1.0], [111, 'Table of Contents', 0, 'Missing Data', 'Missing Data', 1.0], [112, 'Table of Contents', 0, 'Efficacy Analyses', 'Efficacy Analyses', 1.0], [113, 'Table of Contents', 0, 'Analysis of Primary Efficacy Endpoint', '11.6.1 Analysis of Primary Efficacy Endpoint', 1.0], [114, 'Table of Contents', 0, 'Primary Analysis of Primary Efficacy Endpoint', 'Primary Analysis of Primary Efficacy Endpoint', 1.0], [115, 'Table of Contents', 0, 'Sensitivity Analyses of Primary Efficacy Endpoint', 'Sensitivity Analyses of Primary Efficacy Endpoint', 1.0], [116, 'Table of Contents', 0, 'Analysis of Key Secondary Efficacy Endpoints', '11.6.2 Analysis of Key Secondary Efficacy Endpoints', 1.0], [117, 'Table of Contents', 0, 'Analysis of mean change in HGB value between Baseline (mean pretreatment HGB) and the secondary evaluation period (Weeks 40-52)', 'Analysis of mean change in HGB value between Baseline (mean pretreatment HGB) and the secondary evaluation period (Weeks 40-52)', 1.0], [118, 'Table of Contents', 0, 'Analysis of proportion of subjects with mean HGB within the target range during the primary evaluation period (Weeks 24-36)', 'Analysis of proportion of subjects with mean HGB within the target range during the primary evaluation period (Weeks 24-36)', 1.0], [119, 'Table of Contents', 0, 'Analysis of mean weekly dose of IV elemental iron administered from Baseline to Week 52', 'Analysis of mean weekly dose of IV elemental iron administered from Baseline to Week 52', 1.0], [120, 'Table of Contents', 0, 'Analysis of proportion of subjects receiving RBC transfusion(s) from Baseline to Week 52', 'Analysis of proportion of subjects receiving RBC transfusion(s) from Baseline to Week 52', 1.0], [121, 'Table of Contents', 0, 'Analysis of Additional Secondary Efficacy Endpoints', '11.6.3 Analysis of Additional Secondary Efficacy Endpoints', 1.0], [122, 'Table of Contents', 0, 'Safety Analyses', 'Safety Analyses', 1.0], [123, 'Table of Contents', 0, 'Analysis of MACE', '11.7.1 Analysis of MACE', 1.0], [124, 'Table of Contents', 0, 'Analysis of Adverse Events', '11.7.2 Analysis of Adverse Events', 1.0], [125, 'Table of Contents', 0, 'Remaining Safety Endpoints', '11.7.3  Remaining Safety Endpoints', 1.0], [126, 'Table of Contents', 0, 'Additional Assessments', 'Additional Assessments', 1.0], [127, 'Table of Contents', 0, 'Concomitant Medications', '11.8.1 Concomitant Medications', 1.0], [128, 'Table of Contents', 0, 'Biomarkers', '11.8.2 Biomarkers', 1.0], [129, 'Table of Contents', 0, 'Pharmacokinetics', '11.8.3 Pharmacokinetics', 1.0], [130, 'Table of Contents', 0, 'DATA HANDLING AND RECORD KEEPING', '12 DATA HANDLING AND RECORD KEEPING', 1.0], [131, 'Table of Contents', 0, 'Case Report Forms/Electronic Data Capture', 'Case Report Forms/Electronic Data Capture', 1.0], [132, 'Table of Contents', 0, 'Record Retention', 'Record Retention', 1.0], [133, 'Table of Contents', 0, 'QUALITY CONTROL (QC) AND QUALITY ASSURANCE (QA)', '13 QUALITY CONTROL (QC) AND QUALITY ASSURANCE (QA)', 1.0], [134, 'Table of Contents', 0, 'Investigative Site Monitoring Visits', 'Investigative Site Monitoring Visits', 1.0], [135, 'Table of Contents', 0, 'Protocol Deviations', 'Protocol Deviations', 1.0], [136, 'Table of Contents', 0, 'STUDY DISCONTINUATION/INVESTIGATIVE STUDY SITE TERMINATION', '14 STUDY DISCONTINUATION/INVESTIGATIVE STUDY SITE TERMINATION', 1.0], [137, 'Table of Contents', 0, 'Criteria for Premature Termination or Suspension of the Study', 'Criteria for Premature Termination or Suspension of the Study', 1.0], [138, 'Table of Contents', 0, 'Criteria for Premature Termination or Suspension of Investigational Study Sites', 'Criteria for Premature Termination or Suspension of Investigational Study Sites', 1.0], [139, 'Table of Contents', 0, 'Procedures for Premature Termination or Suspension of the Study or', 'Procedures for Premature Termination or Suspension of the Study or', 1.0], [140, 'Table of Contents', 0, 'Investigational Sites', 'Investigational Sites', 1.0], [141, 'Table of Contents', 0, 'ETHICS', '15 ETHICS', 1.0], [142, 'Table of Contents', 0, 'Ethical Conduct of the Study', 'Ethical Conduct of the Study', 1.0], [143, 'Table of Contents', 0, 'Institutional Review Board/Independent Ethics Committee', 'Institutional Review Board/Independent Ethics Committee', 1.0], [144, 'Table of Contents', 0, 'Subject Information and Consent', 'Subject Information and Consent', 1.0], [145, 'Table of Contents', 0, 'Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP', 'Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP', 1.0], [146, 'Table of Contents', 0, 'Subject Confidentiality', 'Subject Confidentiality', 1.0], [147, 'Table of Contents', 0, 'PUBLICATION OF STUDY RESULTS', '16 PUBLICATION OF STUDY RESULTS', 1.0], [148, 'Table of Contents', 0, 'REFERENCES', '17 REFERENCES', 1.0], [149, 'Table of Contents', 0, 'APPENDIX A:  SCHEDULE OF ACTIVITIES', 'APPENDIX A:  SCHEDULE OF ACTIVITIES', 1.0], [150, 'Table of Contents', 0, 'APPENDIX B:  CKD-EPI CREATININE EQUATION', 'APPENDIX B:  CKD-EPI CREATININE EQUATION', 1.0], [151, 'Table of Contents', 2, '', 'APPENDIX C:  ACTH (COSYNTROPIN) STIMULATION TEST FOR', 0.1111111111111111], [152, 'Table of Contents', 2, '', 'ADRENAL FUNCTION MONITORING', 0.2], [153, 'Table of Contents', 2, '', 'APPENDIX D:  HISTORY OF AMENDMENTS TO THE PROTOCOL', 0.11538461538461539]]}\""